Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Imnate Sarl currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. The company's prosecution activity is concentrated, with only 1 distinct examiner and 1 distinct art unit involved. This suggests a focused intellectual property strategy, likely revolving around a single pharmaceutical or biotechnological innovation. The involvement of only 1 distinct art unit indicates that the technology is categorized within a specific biological or chemical niche.
The busiest examiner, ESPINOSA, CLAUDIA EDILMA, is assigned 1 busiest examiner pending action. Since the total pending office actions and the busiest examiner pending count are each 1, this examiner is responsible for the company's entire active workload at the patent office. The presence of only 1 distinct examiner means that the outcome of the portfolio's current prosecution phase depends on the interactions with this official. Practitioners should evaluate the previous actions of ESPINOSA, CLAUDIA EDILMA to anticipate the likely trajectory of this single pending matter.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ESPINOSA, CLAUDIA EDILMA | 1 | 50.9% | +56.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014321 | CD1 PEPTIDE-EPITOPE FOR USE IN THE TREATMENT OF A DISEASE CAUSED BY AN INTRACELLULAR PATHOGEN | ESPINOSA, CLAUDIA EDILMA | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18014321 | CD1 PEPTIDE-EPITOPE FOR USE IN THE TREATMENT OF A DISEASE CAUSED BY AN INTRACELLULAR PATHOGEN | ESPINOSA, CLAUDIA EDILMA | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18014321 | CD1 PEPTIDE-EPITOPE FOR USE IN THE TREATMENT OF A DISEASE CAUSED BY AN INTRACELLULAR PATHOGEN | ESPINOSA, CLAUDIA EDILMA | 1654 | §103§112 | Final Rejection | 31d overdue | Pending | Jan 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImnate Sarl has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Claudia Edilma Espinosa has the most, with 1 of Imnate Sarl's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
